Analysts Offer Insights on Healthcare Companies: Senseonics Holdings (SENS) and Arcutis Biotherapeutics (ARQT)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Senseonics Holdings (SENS – Research Report) and Arcutis Biotherapeutics (ARQT – Research Report) with bullish sentiments.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Senseonics Holdings (SENS)

TD Cowen analyst Josh Jennings reiterated a Buy rating on Senseonics Holdings today and set a price target of $1.25. The company’s shares closed last Monday at $0.57.

According to TipRanks.com, Jennings is a 3-star analyst with an average return of 2.3% and a 47.4% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Anteris Technologies Global Corp., Establishment Labs Holdings, and Zimmer Biomet Holdings. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Senseonics Holdings with a $1.28 average price target.

See today’s best-performing stocks on TipRanks >>

Arcutis Biotherapeutics (ARQT)

In a report released today, Uy Ear from Mizuho Securities maintained a Buy rating on Arcutis Biotherapeutics, with a price target of $26.00. The company’s shares closed last Monday at $19.76.

According to TipRanks.com, Ear is a 1-star analyst with an average return of -1.3% and a 37.6% success rate. Ear covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Cartesian Therapeutics, and MBX Biosciences, Inc. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arcutis Biotherapeutics with a $22.79 average price target, representing a 14.6% upside. In a report released today, Needham also maintained a Buy rating on the stock with a $22.00 price target.

Read More on SENS:

Disclaimer & DisclosureReport an Issue

• Senseonics reports preliminary Q3 revenue $8.1M, consensus $7.81M
• Senseonics announces one-for-twenty reverse stock split
• Senseonics Approves Reverse Stock Split Proposal
• Positive Outlook on Senseonics Holdings Driven by Eversense 365’s Market Adoption and Growth Potential
• Strategic In-House Transition and Financial Strength Bolster Senseonics’ Growth Outlook